Roche Holding Ag Stock News

SOUTH SAN FRANCISCO (dpa-AFX) - Roche (RHHBY) reported follow-up efficacy, safety and patient-reported outcomes data from the phase II CITYSCAPE trial, investigating the anti-TIGIT cancer immunoth

This Chemotherapy-induced Nausea and Vomiting Drugs market report provides a comprehensive assessment of the market''s current state and future prospects. The market and its essential aspects are easily understood by organizations. It also conducts research on the market''s framework within

After 2.5 years median follow-up, pre-planned exploratory analyses in the PD-L1-high population show clinically meaningful results, with overall survival not yet reached and continued progression-f

Basel, 10 December 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced new follow-up efficacy, safety and patient-reported outcomes (PROs) data from the phase II CITYSCAPE trial, investigating the novel anti-TIGIT cancer immunotherapy tiragolumab plus Tecentriq® (atezolizumab) compared with Tecentriq alone as an initial (first-line) treatment for people with PD-L1-positive metastatic non-small cell lung cancer (NSCLC). The full results are being featured as an oral presentation in the Proffered Paper session 2 (Abstract LBA2) at the European Society for Medical Oncology (ESMO) Immuno-Oncology Congress 2021, taking place 8-11 December. 1 These encouraging results suggest that combining anti-TIGIT and anti-PD-L1 cancer immunotherapies such as tiragolumab and Tecentriq could potentially represent a novel approach to address unmet needs in cancer, said Levi Garraway, M.D., Ph.D., Roches Chief Medical Officer and Head of Global Product Development. With tiragolumab, we have the largest and most advanced anti-TIGIT clinical programme, and we look forward to the results of our phase III trials in lung cancer and other challenging tumour types. After 2.5 years median follow-up, tiragolumab plus Tecentriq continued to show an improvement in the intention-to-treat (ITT) population (n=67), driven by the PD-L1-high population (TPS 50%) (n=29).

Roche Holdings AG (OTC: RHHBY) reported follow-up efficacy, safety, and patient-reported outcomes data from the Phase 2 CITYSCAPE trial of tiragolumab plus Tecentriq as an initial treatment for PD-

This remarkable Blood Electrolyte Analyzers market report is the precise depiction of the whole market scenario. Studying potential deficits along with the issues encountered by major industries is possible through this report. It focuses on social, financial and economic elements

According to latest research report published by WMR, Cancer Immunotherapy industry represents facts and data using diagrams, graphs, pie charts, and other pictorial representations. This enhances the visual representation and also helps businesses in understanding the facts much better. Get

Affimed (AFMD) starts recruiting patients in a phase I/IIa study to evaluate the combination of AFM24 and Roche's atezolizumab in solid tumors.

The Global Wearable Biological Sensor Market report offers a comprehensive evaluation of the market. It does give in-depth analysis via qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using

The Global Glucose Meter Market Research Report Forecast 2021 2026 is a valuable source of insightful data for business strategists. It provides the industry overview with growth analysis and historical & futuristic cost, revenue, demand, and supply data (as applicable).

The Global Immuno-Oncology Market Research Report Forecast 2021 2026 is a valuable source of insightful data for business strategists. It provides the industry overview with growth analysis and historical & futuristic cost, revenue, demand, and supply data (as applicable). The

Hyderabad: Hyderabad-based Dr Reddys Laboratories and Prestige BioPharma have entered into a binding agreement for an exclusive partnership for the supply and commercialisation of Prestige BioPharmas proposed trastuzumab biosimilar in select countries in Latin America and Southeast Asia. Prestige BioPharmas trastuzumab (HD201) is a proposed biosimilar to Roches Herceptin and can be prescribed for the []

By working with both Roche and Genentech’s R&D units, Recursion will tap technology-enabled drug discovery through its Operating System (OS) to more quickly identify novel targets and then The post Recursion, Roche, Genentech collaborate in neuroscience, oncology appeared first on Pharmaceutical Business review .

Related Stocks: ROG , NESN , MC , ULVR , OR , SAP , EL , RMS , KER , ESSITYB , ML , SHL , CFR , KESKOB , BATS , DTE , RI , CPG ,

VANCOUVER, BC , Dec. 8, 2021 /PRNewswire/ -- USA News Group - Growing at a healthy CAGR of 14.1%, the Cancer Immunotherapy Market is being projected to hit nearly $310 billion by 2030, according to Allied Analytics . Over the past decade, cancer drug revenues increased 70%, according to a retrospective analysis . Last December, biotechs working on breast cancer treatments saw their shares soar . This year has continued that momentum, with multiple biotech companies driving progress in the fight against cancer, including from Oncolytics Biotech Inc. (NASDAQ: ONCY ) (TSX: ONC ), Incyte Corporation (NASDAQ: INCY ), BriaCell Therapeutics Corp. (NASDAQ: BCTX ), Gilead Sciences, Inc. (NASDAQ: GILD ), and Eli Lilly and Company (NYSE: LLY ). Coming up between December 11-14, 2021 , Oncolytics Biotech Inc. (NASDAQ: ONCY ) (TSX: ONC ) will give an update at the upcoming 63 rd American Society of Hematology Annual Meeting and Exposition (ASH 2021) on its Phase II Triple-Negative Breast Cancer Trial—known as the IRENE study, which is evaluating the company''s flagship product pelareorep, an immunotherapeutic agent that turns "cold" tumors "hot", in combination with the anti-PD-1 checkpoint inhibitor, retifanlimab, from Incyte Corporation (NASDAQ: INCY ).